Your search history is turned on.
Date: May 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
1 Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Eupraxia common shares now listed on the Nasdaq Capital Market (Nasdaq) under the symbol EPRX Additional data from RESOLVE study evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE) expected in the second quarter of 202...
Microsoft Word - postIFRS 52109F2 F - Bruce Cousins (TO BE FILED).doc 1 Form 52-109F2 Certification of Interim Filings Full Certificate I, Bruce Cousins, Chief Financial Officer of Eupraxia Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Eupraxia Phar...
Microsoft Word - postIFRS 52109F2 F - James Helliwell (TO BE FILED).doc 1 Form 52-109F2 Certification of Interim Filings Full Certificate I, James Helliwell, Chief Executive Officer of Eupraxia Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Eupraxia ...
Microsoft Word - EPRX - MDA Q1'24 (FINAL-TO BE FILED).docx 1 EUPRAXIA PHARMACEUTICALS INC. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the three months ended March 31, 2024 2 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, ...
Microsoft Word - US GAAP FS Eupraxia Pharmaceuticals Inc. Mar 31 2024 - FINAL (TO BE FILED).docx EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three Months ended March 31, 2024 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS March 31, 2024 (Unaudited and ...
Date: May 2, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
1 Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board --Advisory Board to Provide Guidance for Companys Eosinophilic Esophagitis Clinical Program-- Victoria, B.C. May 2, 2024 Eupraxia Pharmaceuticals Inc. (Eupraxia or the Company) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging i...
Date: April 11, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
1 Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 Victoria, B.C. April 11, 2024 Eupraxia Pharmaceuticals Inc. (Eupraxia or the Company) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere technology to o...
Date: April 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - 1408-7561-7803-v2-Eupraxia - MCR (Nasdaq Listing Commencement).docx FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Eupraxia Pharmaceuticals Inc. (the Company) 201-2067 Cadboro Bay Rd. Victoria, British Columbia Canada, V8R 5G4 Item 2: Date of Material Change April 5, 2024 Item 3: News Release A n...
VIA ELECTRONIC TRANSMISSION TO ALL APPLICABLE EXCHANGES AND COMMISSIONS: RE: EUPRAXIA PHARMACEUTICALS INC. Confirmation of Notice of Record and Meeting Dates We are pleased to confirm that Notice of Record and Meeting Dates was sent to The Canadian Depository for Securities. We advise the following with respect to the upcoming Annual General and Special Meeting...
1 Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference Victoria, B.C. April 8, 2024 Eupraxia Pharmaceucals Inc. (Eupraxia or the Company) (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere technology to optimize drug delivery for applications with...